<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707664</url>
  </required_header>
  <id_info>
    <org_study_id>PTX-001-003</org_study_id>
    <nct_id>NCT04707664</nct_id>
  </id_info>
  <brief_title>Sargramostim Use in COVID-19 to Recover Patient Health</brief_title>
  <acronym>SCOPE</acronym>
  <official_title>A Randomized Phase 2b Trial Evaluating Clinical Outcomes of Inhaled Sargramostim in High-risk Patients With Mild-moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Partner Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Partner Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to understand if the study drug, also called sargramostim or&#xD;
      Leukine®, can help prevent the worsening of COVID-19 when the study drug is inhaled. This&#xD;
      study will also help researchers understand if inhaled sargramostim can help prevent visits&#xD;
      to the emergency room or hospitalization, or death.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2b, multicenter, placebo-controlled, double-blind study will randomize&#xD;
      approximately 500 adult patients who are symptomatic with mild or moderate COVID-19 (as&#xD;
      defined in the FDA Guidance Document: Covid-19: Developing Drugs and Biological Products for&#xD;
      Treatment or Prevention, May 2020) who are at high risk for progression to more severe&#xD;
      disease. Patients will be randomized in a 1:1 ratio to inhaled sargramostim plus standard of&#xD;
      care (SOC) or placebo plus SOC. Enrollment of patients who have completed a COVID-19&#xD;
      vaccination regimen or participated in a COVID-19 vaccine clinical trial will be capped at&#xD;
      approximately 100 patients. All patients will be randomized to receive either 250 mcg of&#xD;
      sargramostim or equivalent volume of placebo diluent. Treatment will be administered once&#xD;
      daily for 5 days delivered via a vibrating mesh nebulizer. Patients will be followed for up&#xD;
      to 60 days after start of treatment.&#xD;
&#xD;
      Sargramostim (Leukine) is a formulation of Granulocyte Macrophage Colony Stimulating Factor&#xD;
      (GM-CSF), which is a critical cytokine for healthy pulmonary function. Detailed studies have&#xD;
      shown that GM-CSF is necessary for alveolar macrophage (AM) maturation and maintenance.&#xD;
      Although GM-CSF was discovered as a myelopoietic growth factor, it has diverse additional&#xD;
      effects that both promote differentiation of myeloid precursors into neutrophils, monocytes,&#xD;
      and dendritic cells and control function of mature myeloid cells. GM-CSF is also known to&#xD;
      reverse immunoparalysis seen in sepsis, resulting in beneficial outcomes. In addition, GM-CSF&#xD;
      prevents bacteremia in post influenza bacterial pneumonia through locally mediated improved&#xD;
      lung antibacterial resistance and increased reactive oxygen species production by AMs.&#xD;
      Pulmonary delivery of this GM-CSF has potential to reduce morbidity and mortality due to&#xD;
      viral pneumonias, potentially including COVID-19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This Phase 2b, multicenter, placebo-controlled, double-blind study will randomize approximately 500 adult patients who are symptomatic with mild or moderate COVID-19 (as defined in the FDA Guidance Document: Covid-19: Developing Drugs and Biological Products for Treatment or Prevention, May 2020) who are at high risk for progression to more severe disease. Patients will be randomized in a 1:1 ratio to inhaled sargramostim plus standard of care (SOC) or placebo plus SOC. Enrollment of patients who have completed a COVID-19 vaccination regimen or participated in a COVID-19 vaccine clinical trial will be capped at approximately 100 patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Any emergency room visit or hospitalization, or death</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of patients who experience any emergency room visit or hospitalization, or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Progression based on NIAID Score</measure>
    <time_frame>28, 60 days</time_frame>
    <description>Proportion of patients with any progression of disease as determined by a ≥ 2-point increase from baseline in the NIAID ordinal scale up to Day 28, and Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression based on NIAID Score</measure>
    <time_frame>28, 60 days</time_frame>
    <description>Time to progression of disease as determined by a ≥ 2-point increase in the NIAID ordinal scale up to Day 28, and Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Symptom Scores</measure>
    <time_frame>28 days</time_frame>
    <description>Change from baseline in overall symptom score, and individual symptom scores, as measured by the Symptom Score Questionnaire up to Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>60 days</time_frame>
    <description>Adverse events up to Day 60</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Sargramostim Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Day 1 - 5: Placebo treatment in addition to standard of care for COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days.</description>
    <arm_group_label>Sargramostim Arm</arm_group_label>
    <other_name>Leukine</other_name>
    <other_name>GM-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a positive laboratory diagnosis of SARS-CoV-2 infection by an antigen or&#xD;
             a molecular test ≤5 days prior to randomization. The test should have been authorized&#xD;
             by the relevant regulatory authority.&#xD;
&#xD;
          2. Have one or more of the following mild or moderate COVID-19 symptoms for ≤5 days prior&#xD;
             to randomization:&#xD;
&#xD;
               1. Fever or chills&#xD;
&#xD;
               2. New onset or worsening cough&#xD;
&#xD;
               3. Sore throat&#xD;
&#xD;
               4. Malaise or fatigue&#xD;
&#xD;
               5. Headache&#xD;
&#xD;
               6. Muscle pain (myalgias) or body aches&#xD;
&#xD;
               7. Gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea)&#xD;
&#xD;
               8. New onset or worsening shortness of breath or difficulty breathing&#xD;
&#xD;
               9. Nasal congestion or runny nose&#xD;
&#xD;
              10. New loss of taste (ageusia) and/or smell (anosmia). Note: any of these symptoms&#xD;
                  (ageusia, anosmia) alone or in combination cannot be used as the SOLE qualifying&#xD;
                  symptoms for enrollment.&#xD;
&#xD;
          3. At higher risk for progression to more severe COVID-19&#xD;
&#xD;
               1. Age ≥ 60 years&#xD;
&#xD;
               2. Age 18-59 years with a clinically stable medical history of at least 1 or more of&#xD;
                  the following conditions that could lead to severe COVID-19:&#xD;
&#xD;
                    -  Chronic respiratory conditions such as asthma, chronic obstructive pulmonary&#xD;
                       disease (COPD), pulmonary fibrosis&#xD;
&#xD;
                    -  Obesity with BMI ≥ 30 kg/m2&#xD;
&#xD;
                    -  Cardiovascular disease&#xD;
&#xD;
                    -  Sickle cell disease or thalassemia&#xD;
&#xD;
                    -  Diabetes mellitus being managed with concomitant medications&#xD;
&#xD;
                    -  Hypertension being managed with concomitant medications&#xD;
&#xD;
                    -  Chronic kidney disease&#xD;
&#xD;
          4. Oxygen saturation by pulse oximeter &gt; 93% on room air. Note: at altitudes of &gt;4000&#xD;
             feet above sea level, oxygen saturation by pulse oximeter &gt; 91% on room air is&#xD;
             permitted&#xD;
&#xD;
          5. Negative pregnancy test (if woman of childbearing potential)&#xD;
&#xD;
          6. Females of childbearing potential and males with female partners of childbearing&#xD;
             potential must agree to use acceptable contraceptive methods from screening to Day 28&#xD;
&#xD;
          7. The patient (or legally authorized decision maker) must give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hospitalized patients&#xD;
&#xD;
          2. Patients who have received or are receiving other treatments that are not&#xD;
             approved/authorized by the relevant regulatory authority for the treatment of patients&#xD;
             with mild or moderate COVID-19 in an outpatient setting&#xD;
&#xD;
          3. Patients enrolled in interventional clinical trials for other experimental therapies&#xD;
&#xD;
          4. Patients on chronic oxygen supplementation due to cardiopulmonary or other conditions&#xD;
&#xD;
          5. Patients with unstable comorbid conditions (e.g., decompensated congestive heart&#xD;
             failure, COPD with exacerbation, current angina pectoris, uncontrolled diabetes&#xD;
             mellitus, uncontrolled hypertension, uncontrolled asthma)&#xD;
&#xD;
          6. Patients with severe pulmonary comorbid conditions, including systemic&#xD;
             steroid-dependent asthma, systemic steroid-dependent COPD, oxygen-dependent COPD, lung&#xD;
             transplant, or cystic fibrosis&#xD;
&#xD;
          7. Patients who have received highly immunosuppressive therapy (to include systemic&#xD;
             corticosteroids) or anti-cancer combination chemotherapy within 24 hours prior to&#xD;
             first dose of study drug&#xD;
&#xD;
          8. Patients with known or suspected intolerance or hypersensitivity to sargramostim, or&#xD;
             any component of the product&#xD;
&#xD;
          9. Patients who have previously experienced severe and unexplained side effects during&#xD;
             aerosol delivery of any kind of medical product&#xD;
&#xD;
         10. Pregnant or breastfeeding females&#xD;
&#xD;
         11. Patients who, in the opinion of the Investigator, will not be able to comply with all&#xD;
             the study procedures and visits as outlined in the schedule of events, including&#xD;
             follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fiona Garner, PhD</last_name>
    <phone>(781) 819-4949</phone>
    <phone_ext>1588</phone_ext>
    <email>scopestudy@partnertx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West Valley Research Clinic, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Zacher, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Wilbur, MD</last_name>
      <phone>501-954-7822</phone>
      <email>drwilbur@arcarkansas.com</email>
    </contact>
    <investigator>
      <last_name>Lee Wilbur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hessam Aazami, MD</last_name>
      <phone>818-999-4673</phone>
      <email>haazami@hopclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Colton</city>
        <state>California</state>
        <zip>92324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian J. Bearie, M.D.</last_name>
      <phone>909-503-9240</phone>
      <email>brianbearie@BenchmarkResearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synergy Healthcare</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick S. Weston, M.D.</last_name>
      <phone>941-896-4948</phone>
      <email>pweston@synergyhealthcorp.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Invesclinic US, LLC.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Garcia, M.D.</last_name>
      <phone>954-938-2843</phone>
      <email>bgarcia@invesclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indago Research &amp; Health Center, Inc. (Subject Visits Only)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose F. Cardona, M.D.</last_name>
      <phone>305-825-6588</phone>
      <email>jcardona@indagoresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Encore Medical Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodolfo A. Perez, M.D.</last_name>
      <phone>954-400-1725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IMIC Inc.</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Leon, M.D.</last_name>
      <phone>786-310-7477</phone>
      <email>ramon@aktamedika.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Encore Medical Research of Weston</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro Bacchelli, M.D.</last_name>
      <phone>954-400-1725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gwinnett Research Institute, LLC</name>
      <address>
        <city>Buford</city>
        <state>Georgia</state>
        <zip>30519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander E. Osowa, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paramount Research Solutions</name>
      <address>
        <city>College Park</city>
        <state>Georgia</state>
        <zip>30349</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Y. Evans, M.D.</last_name>
      <phone>404-657-4500</phone>
      <email>myevans.prs@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TidalHealth Peninsula Regional, Inc.</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Trumble, M.D.</last_name>
      <phone>240-344-5448</phone>
      <email>james.trumble@peninsula.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute, Inc.</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry W. Feldman, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Revival Research Institute, LLC.</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdulhassan Saad, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Olive Branch Family Medical Center</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <zip>38654</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randall T. Huling, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Plains Health</name>
      <address>
        <city>North Platte</city>
        <state>Nebraska</state>
        <zip>69101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Molina-Pallete, MD</last_name>
      <phone>308-252-2456</phone>
      <email>molinag@gphealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Excel Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duane Anderson, MD</last_name>
      <phone>702-680-1500</phone>
      <email>danderson@excelclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richmond University Medical Center</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Nfonoyim, MD</last_name>
      <phone>718-818-4355</phone>
      <email>jnfonoyim@rumcsi.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monroe Biomedical Research</name>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <zip>28112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Awawu Igbinadolor, MD</last_name>
      <phone>704-283-7359</phone>
      <email>awawu.Igbinadolor@monroeresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care and Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blaise M. Gatto, D.O.</last_name>
      <phone>937-912-4444</phone>
      <email>bgatto@hometownurgentcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care and Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narinder Saini, M.D.</last_name>
      <phone>614-745-8863</phone>
      <email>Nsaini@HometownUrgentCare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urgent Care Specialists, LLC DBA Hometown Urgent Care and Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve H. Choi, M.D.</last_name>
      <phone>937-236-8630</phone>
      <email>schoi@hometownurgentcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TruCare Internal Medicine and Infectious Disease</name>
      <address>
        <city>DuBois</city>
        <state>Pennsylvania</state>
        <zip>15801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuesdae Stainbrook</last_name>
      <phone>814-371-2348</phone>
      <email>drstainbrook@trucareinternalmedicine.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urgent Care Clinical Trials @ AFC Urgent Care - Easley</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Harris, MD</last_name>
      <phone>864-307-8672</phone>
      <email>drharris@UCCTrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Diabetes &amp; Endocrine Consuttants</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David M. Huffman, M.D.</last_name>
      <phone>423-265-3561</phone>
      <email>dhuffman@drhuffman.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCCT @ City Doc Urgent Care-McKinney</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiwali Rai, MD</last_name>
      <phone>214-871-7000</phone>
      <email>drrai@UCCTrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Invesclinic US LLC</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monzer Yazji, MD</last_name>
      <phone>984-513-4732</phone>
      <email>myazji@invesclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dorrington Medical Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Varon, MD</last_name>
      <phone>832-606-1300</phone>
      <email>jvaron@roamer.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Encore Imaging &amp; Medical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelechi Azuogu, M.D.</last_name>
      <phone>832-938-5670</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMS Clinical Research, LLC</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salma Saiger, M.D.</last_name>
      <phone>972-216-5152</phone>
      <email>ssaiger@smsclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novotrial Research Group</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77584</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Obi-Ofodile, MD</last_name>
      <phone>346-704-3774</phone>
      <email>info@novotrialrg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl E Dukes, FACP</last_name>
      <phone>210-227-1289</phone>
      <email>cdukes@sunresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Paine, MD</last_name>
      <phone>801-581-5811</phone>
      <email>robert.paine@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Medicas Mar del Plata</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Alvarisqueta, Physician</last_name>
      <phone>54 223 491 7628</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Medico de la Fundacion Estudios Clinicos</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Alvarez</last_name>
      <phone>3412384171</phone>
      <email>tomasalvarez@consultoriosintegrados.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorio Santa Barbara</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1414DTK</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Femando Lipovestky</last_name>
      <phone>15-4064-7117</phone>
      <email>Femando.lipovestky@uaisalud.com.ar</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV2</keyword>
  <keyword>sargramostim</keyword>
  <keyword>Leukine</keyword>
  <keyword>(recombinant human) GM-CSF</keyword>
  <keyword>immune modulator</keyword>
  <keyword>SCOPE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

